HYPERTENSION ARTERIELLE ET ALCOOLISME CHRONIQUE (PATHOGENIE ET PROPOSITIONS THERAPEUTIQUES ; ETUDE DE CAS)

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

BactoTrait - A functional trait database to evaluate how contaminants govern the assembly of bacterial communities

International audienc

BactoTraits – A functional trait database to evaluate how natural and man-induced changes influence the assembly of bacterial communities

International audienc

Pyxel 1.0: an open source Python framework for detector and end-to-end instrument simulation

Detector modelling is becoming more and more critical for the successful development of new instruments in scientific space missions and ground-based experiments. Specific modelling tools are often developed from scratch by each individual project and not necessarily shared for reuse by a wider community. To foster knowledge transfer, reusability and reliability in the instrumentation community, ESA and ESO joined forces and developed Pyxel, a framework for the simulation of scientific detectors and instruments. Pyxel is an open-source and collaborative project, based on Python, developed as an easy-to-use tool that can host and pipeline any kind of detector effect model. Recently Pyxel has achieved a new milestone: the public release and launch of version 1.0 which simplified third-party contributions and improved ease of use even further. Since its launch, Pyxel has been experiencing a growing user community and is being used to simulate all kinds of detectors beyond the traditional Charged-Coupled Devices and CMOS devices, for example Microwave Kinetic Inductance Detectors (MKID) and Avalanche Photo Diode (APD) devices. We give a tour of Pyxel’s version 1.0 changes and new features including a new interface, parallel computing, and new detectors and models. We continue with an example of using Pyxel as a tool for model optimization and calibration. Finally, we describe an example of how Pyxel and its features can be used to develop a full-scale end-to-end instrument simulator

Diversity-function relationships in contaminated soils – A functional trait approach

International audienc

Intérêt des mésocosmes « transportables » pour l'étude des impacts toxiques sur les écosystèmes aquatiques

International audienc

Relation diversité−fonction dans les sols contaminés – Une approche base sur les traits fonctionnels

National audienc

A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study

Background NCTF®135HA is a bio-revitalizing solution containing hyaluronic acid designed to compensate for skin dehydration, fatigue, and fine wrinkles associated with endogenous and environmental aging. Methods We conducted a randomized, active-controlled study to evaluate the efficacy and tolerability of NCTF®135HA injections on the face (crow’s feet), neck, and décolleté regions. Subjects were randomly assigned (3:1) to receive three NCTF®135HA treatment sessions plus twice-daily anti-aging moisturizer cream or cream alone (control). The primary outcome was the reduction in superficial wrinkles between baseline and Day (D)75 in the three areas, assessed by profilometric measures, clinical scoring, subjective changes, and tolerability. Results 146 subjects were randomized to NCTF®135HA (n = 107) or control (n = 38). At D75 and D120, NCTF®135HA significantly reduced wrinkles in all three areas and improved facial radiance scores compared with the control. Skin hydration significantly increased 7 d after the last NCTF®135HA injection. Self-esteem scales showed statistically significant improvements at D75 and D120 in subjects treated with NCTF®135HA versus baseline. Most adverse events were mild, resolved within 48 h, and were related to the injection procedure. Conclusion NCTF®135HA is an effective and well-tolerated treatment to reduce the skin signs of aging. The results are significantly superior to a routine anti-aging cream alone. (Funded by Laboratories FILLMED; ID-RCB number: 2018-A03167-48; clinicaltrials.gov number: NCT05609617

Direct transfer to angiosuite for patients with severe acute stroke treated with thrombectomy: the multicentre randomised controlled DIRECT ANGIO trial protocol

International audienceIntroduction Mechanical thrombectomy (MT) increases functional independence in patients with acute ischaemic stroke with anterior circulation large vessel occlusion (LVO), and the probability to achieve functional independence decreases by 20% for each 1-hour delay to reperfusion. Therefore, we aim to investigate whether direct angiosuite transfer (DAT) is superior to standard imaging/emergency department-based management in achieving 90-day functional independence in patients presenting with an acute severe neurological deficit likely due to LVO and requiring emergent treatment with MT. Methods and analysis DIRECT ANGIO (Effect of DIRECT transfer to ANGIOsuite on functional outcome in patient with severe acute stroke treated with thrombectomy: the randomised DIRECT ANGIO Trial) trial is an investigator-initiated, multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) study. Eligibility requires a patient ≤75 years, pre-stroke modified Rankin Scale (mRS) 0–2, presenting an acute severe neurological deficit and admitted within 5 hours of symptoms onset in an endovascular-capable centre. A total of 208 patients are randomly allocated in a 1:1 ratio to DAT or standard management. The primary outcome is the rate of patients achieving a functional independence, assessed as mRS 0–2 at 90 days. Secondary endpoints include patients presenting confirmed LVO, patients eligible to intravenous thrombolysis alone, patients with intracerebral haemorrhage and stroke-mimics, intrahospital time metrics, early neurological improvement (reduction in National Institutes of Health Stroke Scale by ≥8 points or reaching 0–1 at 24 hours) and mRS overall distribution at 90 days and 12 months. Safety outcomes are death and intracerebral haemorrhage transformation. Medico-economics analyses include health-related quality of life and cost utility assessment. Ethics and dissemination The DIRECT ANGIO trial was approved by the ethics committee of Ile de France 1. Study began in April 2020. Results will be published in an international peer-reviewed medical journal. Trial registration number NCT03969511